pms-Ursodiol C

pms-Ursodiol C Dosage/Direction for Use

ursodeoxycholic acid

Manufacturer:

Pharmascience

Distributor:

T-BOMA
Full Prescribing Info
Dosage/Direction for Use
Dosing Considerations: Patient Monitoring: Serum liver function tests (γ-GT, alkaline phosphatase, AST, ALT) and bilirubin levels should be monitored every month for three months after start of therapy, and every six months thereafter. Serial monitoring will allow for the early detection of a possible deterioration of the hepatic function. Serum levels of these parameters usually decrease rapidly. Improved serum liver tests (e.g. AST, ALT) do not always correlate with improved disease status. For patients who have a recent history of adequate biochemical response to the treatment, UDCA discontinuation should be considered when serum liver function tests increase to a level considered clinically significant (see Indications/Uses; Hepatic/Biliary/Pancreatic under Precautions).
Caution has to be exercised to maintain the bile flow of the patients taking UDCA.
Recommended Dose: The recommended adult dosage for pms-URSODIOL C (ursodiol) in the treatment of PBC is 13 mg/kg/day to 15 mg/kg/day administered in two to four divided doses with food.
Missed Dose: If a dose is missed, take the missed dose as soon as it is remembered. If it is almost time for the next dose, skip the dose missed and take the next regularly scheduled dose. Do not take a double dose.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in